0
Critical Situations |

Stroke and Deep Venous Thrombosis Complicating Intravenous Immunoglobulin Infusions

Kenneth A. Katz, MD, MSc; Chad M. Hivnor, MD; David E. Geist, BA; Michael Shapiro, MD; Michael E. Ming, MD; Victoria P. Werth, MD
Arch Dermatol. 2003;139(8):991-993. doi:10.1001/archderm.139.8.991.
Text Size: A A A
Published online

Extract

Dalakas  MC High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44223- 226
PubMed
Elkayam  OParan  DMilo  R  et al.  Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune diseases: a study of four cases. Ann Rheum Dis. 2000;5977- 80
PubMed
Woodruff  RKGrigg  APFirkin  FCSmith  IL Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2217- 218
PubMed
Go  RSCall  TG Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc. 2000;7583- 85
PubMed
Oh  KTBoldt  HCDanis  RP Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol. 1997;124416- 418
PubMed
Bystryn  JCJiao  DNatow  S Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47358- 363
PubMed
Tristani-Firouzi  PPetersen  MJSaffle  JRMorris  SEZone  JJ Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47548- 552
PubMed
Prins  CKerdel  FAPadilla  RS  et al.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol. 2003;13926- 32
PubMed
Dahl  MVBridges  AG Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol. 2001;45775- 783
PubMed
Yu  ZLennon  VA Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340227- 228
PubMed
Rutter  ALuger  TA High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol. 2001;441010- 1024
PubMed
Reinhart  WHBerchtold  PE Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. 1992;339662- 664
PubMed
Not Available, FDA interim statement regarding immune globulin intravenous (IGIV); August 27, 2002. Available at:http://www.fda.gov/cber/infosheets/igiv082702.htmAccessed November 13, 2002
Not Available, Important drug warning: actue renal failure with IGIV. Available at:http://www.fda.gov/cber/ltr/igivrenal.htmAccessed November 25, 2002
Dalakas  MC The use of intravenous immunoglobulin for neurologic diseases. Neurology. 1998;51S2- S8
PubMed
Bresee  JSMast  EEColeman  PJ  et al.  Hepatitis C virus infection associated with administration of intravenous immune globulin: a cohort study. JAMA. 1996;2761563- 1567
PubMed
Knable  AL Miscellaneous systemic drugs. Wolverton  SEed.Comprehensive Dermatologic Drug Therapy Philadelphia, Pa WB Saunders Co2001;457- 60

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 25

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Deep Venous Thrombosis

Users' Guides to the Medical Literature
Scenario 2